Özdemir, Ö.; Zengel, B.; Yildiz, Y.; Uluç, B.O.; Cabuk, D.; Ozden, E.; Salim, D.K.; Paydas, S.; Demir, A.; Diker, O.; Pilanci, K.N.; Sönmez, Ö.U.; Vatansever, S.; Dogan, I.; Gulmez, A.; Cakar, B.; Gursoy, P.; Yildirim, M.E.; Ayhan, M.; Karadurmus, N.; Aykan, M.B.; Cevik, G.T.; Sakalar, T.; Hacibekiroglu, I.; Gülbagci, B.B.; Dincer, M.; Garbioglu, D.B.; Kemal, Y.; Nayir, E.; Taskaynatan, H.; Yilmaz, M.; Avci, O.; Sari, M.; Coban, E.; Atci, M.M.; Esen, S.A.; Telli, T.A.; Karatas, F.; Inal, A.; Demir, H.; Kalkan, N.O.; Yilmaz, C.; Tasli, F.; Alacacioglu, A.
(2022)
In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted ...